UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2021
OPKO Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3352875-2402409
(State or Other Jurisdiction
of Incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
4400 Biscayne Blvd.Miami,Florida33137
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (305) 575-4100
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareOPKNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o


ITEM 7.01.
Regulation FD Disclosure.
On January 13, 2021, members of management for OPKO Health, Inc. (the “Company”) took part in the 39th Annual J.P. Morgan Healthcare Conference and participated in one on one meetings with investors. A copy of the Company’s presentation as used in the meetings is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The presentation is also available on the Company’s website at www.opko.com under Investor Relations. The information contained on the Company’s website shall not be deemed part of this report.
The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.
ITEM 8.01.
Other Events.
On January 13, 2021, the Company’s BioReference Laboratories, Inc. introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic services.
ITEM 9.01.
Financial Statements and Exhibits.
(d)Exhibits
Exhibit No.Description
99.1
OPKO Health, Inc. Presentation Materials
99.2Press Release of the Company dated January 13, 2021
104Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document




Exhibit Index
Exhibit No.Description
99.1
99.2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc.
By:
/s/ Steven D. Rubin
Date: January 13, 2021
Name:
Steven D. Rubin
Title:
Executive Vice President-Administration